News

GlobalData on MSN3d
First subject dosed in Vantage’s Phase II trial for diabetic retinopathy
Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...
Morningstar6d
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...
Medical Dialogues12d
Glycemic Variability Marker Linked To Higher Neovascular Glaucoma Risk In Proliferative Diabetic Retinopathy Patients: Study
Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...
Ophthalmology Times13h
Effect of race on visual outcomes in DME treated with ranibizumab
The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...
Eyeing the crisis: How India’s healthcare system is failing 100 million diabetics battling retinopathy
India holds the unenviable position of being home to the world’s largest diabetic population, with nearly 100 million ...